References
- Linchtman SM. Guidelines for the treatment of elderly cancer patient. Cancer Control 2003; 10: 445–453.
- Extermann M. Management issues for elderly patients with breast cancer. Curr Treat Options Oncol 2004; 5: 161–169.
- Chan S, Friedrichs K, Noel D et al. Prospective ran-domized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17: 2341–2354.
- Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413–1424.
- Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline fail-ure: a randomised phase III study with crossover on progres-sion by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194–1201.
- Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87 (11): 1210-1215.
- O'Brien MER, Leonard RCF, Barrett-Lee PJ et al. Docetaxel in the community setting : An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 1999; 10: 205–210.
- Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18: 1212–1219.
- Hainsworth JD, Burris HA, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19: 3500–3505.
- Stemmler HJ, Gutschow K, Sommer H et al. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 2001; 12: 1393–1398.
- Aihara T, Kim Y, Takatsuka Y. Phase II study of week-ly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002; 13: 286–292.
- Maisano R, Mare M, Zavettieri M et al. Is weekly doc-etaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 2003; 23: 1923–1926.
- National Cancer Institute: Common toxicity criteria, version 2.0, 1999.
- Miller AB, Hoogstroten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
- Simon R. Optimal two-stage designs for phase II clinical trials. Contr Clin Trials 1989; 10: 1–10.
- Newman RA, Amir Ahmadi M, Rivera E et al. Identification of docetaxel in tears from patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21: 65 a, (abstr. 256).
- Esmaeli B, Hortobagyi G N, Estava F et al. Canalicular stenosis secondary to weekly docetaxel: a potentially pre-ventable side effect. Ann Oncol 2002; 13: 218–221.
- Flory SM, Solimando DA Jr, Webster CF et al. Onycholisis associated with weekly administration of paclitaxel. Ann Pharmacother 1999; 33: 584–586.
- Correia O, Azevedo C, Pinto Ferreira E et al. Nail changes secondary to docetaxel (Taxotere). Dermatology 1999; 198: 288–290.
- Wasner G, Hilipert F, Baron R, Pfister J. Clinical picture: Nail changes secondary to docetaxel. Lancet 2001; 357: 910.
- Spadaro P, Maisano R, Mare M et al. Is there correla-tion between decreased serum vascular endothelial growth fac-tor (sVEGF) levels and nail toxicity in responsive metastatic breast cancer (MBC) patients treated with weekly docetaxel? Preliminary data of a phase II study. Proc Am Soc Clin Oncol 2002; 21: 35 b, (abstr. 1952).
- Hussain S, Anderson DN, Salvatti ME et al. Onycholysis as a complication of systemic chemotherapy. Cancer 2000; 88: 2367–2371.